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Mutations in PHEX (phosphate-regulating gene with homolo-
gies to endopeptidases on the X chromosome) and DMP1 (dentin
matrix protein 1) result in X-linked hypophosphatemic rickets
(HYP) and autosomal-recessive hypophosphatemic-rickets
(ARHR), respectively. Specific binding of PHEX to matrix ex-
tracellular phosphoglycoprotein (MEPE) regulates the release
of small protease-resistant MEPE peptides [acidic serine- and
aspartate-rich MEPE-associated motif (ASARM) peptides].
ASARM peptides are potent inhibitors of mineralization (min-
hibins) that also occur in DMP1 [MEPE-related small integrin-
binding ligand, N-linked glycoprotein (SIBLING) protein]. It is
not known whether these peptides are directly responsible for
the mineralization defect. We therefore used a bone marrow
stromal cell (BMSC) coculture model, ASARM peptides, anti-
ASARM antibodies, and a small synthetic PHEX peptide (SPR4;
4.2 kDa) to examine this. Surface plasmon resonance (SPR) and
two-dimensional 1H/15N nuclear magnetic resonance demon-
strated specific binding of SPR4 peptide to ASARM peptide.
When cultured individually for 21 d, HYP BMSCs displayed re-
duced mineralization compared with wild type (WT) (87%, P <
0.05). When cocultured, both HYP and WT cells failed to miner-
alize. However, cocultures (HYP and WT) or monocultures of
HYP BMSCs treated with SPR4 peptide or anti-ASARM neutral-
izing antibodies mineralized normally. WT BMSCs treated with
ASARM peptide also failed to mineralize properly without SPR4
peptideoranti-ASARMneutralizingantibodies.ASARMpeptide
treatment decreased PHEX mRNA and protein (80%, P < 0.05)
and SPR4 peptide cotreatment reversed this by binding ASARM
peptide. SPR4 peptide also reversed ASARM peptide-mediated
changes in expression of key osteoclast and osteoblast differen-
tiation genes. Western blots of HYP calvariae and BMSCs re-
vealed massive degradation of both MEPE and DMP1 protein
compared with the WT. We conclude that degradation of MEPE
and DMP-1 and release of ASARM peptides are chiefly respon-
sible for the HYP mineralization defect and changes in osteo-
blast-osteoclast differentiation. (Endocrinology 149: 1757–1772,
2008)
A MUTATED PHEX (phosphate-regulating gene withhomologies to endopeptidases on the X chromosome)
gene is responsible for the primary mineralization and renal
phosphate homeostasis defects noted in X-linked hypophos-
phatemic rickets (HYP) in mice and humans (1). Over 250
human families and at least five mice models with diverse
mutations in this conserved gene overwhelmingly support
this conclusion (1, 2). An extensive PHEX database website
is also available at the web site http://www.phexdb.
mcgill.ca/. PHEX belongs to a well-defined family of Zn
metalloendopeptidases (M13 family; MA clan) involved in
cancer, bone-renal diseases, cardiovascular disease, Alzhei-
mer’s, arthritis, and inflammatory disorders (3, 4). The pro-
totypic member of this class of structurally complex proteins
is neprilysin (CD10, CALLA). To date the physiological sub-
strate and the precise molecular role for PHEX in mineral-
ization and renal phosphate homeostasis remains unknown.
Our previous work showed direct binding of PHEX to matrix
extracellular phosphoglycoprotein (MEPE) (5), a protein ex-
pressed in bone, teeth, and renal proximal convoluted tu-
bules (3, 6). MEPE belongs to a group of extracellular matrix
proteins [small integrin-binding ligand, N-linked glycopro-
teins (SIBLINGs)] involved in bone and teeth mineralization.
These proteins all map to a tightly clustered region on chro-
mosome 4q and include MEPE, dentin matrix protein 1
(DMP1), osteopontin (OPN), bone sialoprotein (BSP), enam-
elin, dentin sialo phosphoprotein (DSPP) and statherin.
MEPE is a phosphate uptake inhibitory factor cloned from a
tumor resected from a patient with tumor-induced osteo-
malacia and hypophosphatemia (7). A key feature of MEPE
and several SIBLINGs including DMP1 is an acidic serine-
and aspartate-rich MEPE-associated motif (ASARM motif)
(3, 7). This motif, when released as a protease-resistant phos-
phorylated peptide (ASARM peptide) negatively affects
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mineralization and phosphate uptake (3, 5, 8, 9). We have
shown indirectly that PHEX binds to MEPE via the ASARM
motif (5) and also potently inhibits PHEX enzymatic hydro-
lysis of a nonphysiological synthetic peptide substrate (10).
This interaction also prevents cathepsin B-mediated hydro-
lysis and release of protease-resistant ASARM peptide (5, 8,
11).
Without functional PHEX (HYP mice), an increase in both
MEPE and osteoblastic protease expression occurs (3, 8, 10–
20). This leads to excess ASARM peptides from MEPE and
perhaps other SIBLINGs like DMP1 (3, 5, 8, 14, 17, 21). Thus,
bone accumulation of the protease-resistant ASARM pep-
tides likely plays a key role in the defective mineralization or
hyperosteoidosis in HYP (3, 5, 8, 9). The precise relationship
between PHEX and MEPE however remains unclear as well
as the link between PHEX, MEPE, and phosphate handling.
For example, one report describes MEPE-null mutations
(mice) result in a marked age-dependent high bone mass
phenotype with an increased in vivo mineral apposition rate
(22). Also, this study and a second independent study report
a marked and significant acceleration of in vitro mineraliza-
tion of MEPE-null mutant bone cells in culture (22, 23). Of
note, although both studies reported a defective in vitro bone
phenotype, the marked increase of in vivo bone mass re-
ported by Gowen et al. (22) was not observed by Liu et al. (23).
However, a key difference between the studies was the age
of the mice used and the techniques for assessing the phe-
notypes. Specifically, Liu et al. (23) used significantly
younger animals (12 wk) compared with the Gowen et al. (22)
(4 months and 12 months). Because bone mass is the result
of two distinct processes, modeling (early growth) and re-
modeling (mainly adult), these findings suggest MEPE ac-
tion is more important for mature bone remodeling. Adult
MEPE-null mice also have increased cancellous and cortical
bone mass without changes in serum phosphate levels (22).
Consistent with this, MEPE ASARM peptides are potent
mineralization inhibitors in vitro and in vivo (3, 5, 8–10).
Although the MEPE-null mutant mouse is normophos-
phatemic, recombinant MEPE introduced by bolus ip injec-
tions induces phosphaturia in rodents (3, 9, 24). Also, the
HYP in vitro mineralization phenotype is corrected by trans-
fer of HYP mice onto a MEPE-deficient mouse background,
but the in vivo phenotype is not (23). This may be because of
the continued proteolytic degradation of the extracellular
protein matrix (increased osteoblast protease expression in
HYP), release of SIBLING ASARM peptides (DMP1), and
ongoing fibroblast growth factor 23 (FGF23)-mediated hy-
pophosphatemia (3, 8). More recently, reintroduction of the
PHEX transgene into PHEX-defective HYP mice produced
surprising results (13, 25, 26). Specifically, overexpression of
human PHEX under the -actin promoter in HYP mice res-
cued the bone phenotype almost completely but did not
correct the hypophosphatemia or the increased FGF23 ex-
pression (13, 25). The authors concluded that “different, pos-
sibly independent, pathophysiological mechanisms contrib-
ute to renal phosphate wasting and bone abnormalities in
HYP” (25). Indeed, others suggested that PHEX may play
dual roles (phosphate regulation and mineralization) depen-
dent on the tissue of expression (13, 25). Recently, we and
others have shown protease treatment of HYP mice partially
corrects the mineralization defect despite persistent hy-
pophosphatemia, again suggesting a phosphate mineraliza-
tion disconnect (8, 15, 19, 20). Early and classic studies with
HYP mice and human patients are consistent with this no-
tion. These studies showed that although dietary phosphate
supplementation corrects rickets and the endochondral cal-
cification, the endosteal hyperosteoidosis remains (27–33).
This is also true for the DMP1-null mouse, a murine model
of autosomal recessive hypophosphatemic rickets (ARHR)
(34). Of note, recent studies show hypophosphatemia is
mainly responsible for the rickets (as opposed to the endo-
chondral mineralization defect). This is because low serum
phosphate impairs caspase-mediated apoptosis of hypertro-
phic chondrocytes (35). Consistent with this, intrinsic odon-
toblast defects that are independent of serum phosphate
levels are chiefly responsible for the dentinal mineralization
defects in the HYP mouse (36). Further confirmation comes
from recent studies on teeth from patients with HYP (21).
Specifically, massive degradation of MEPE and an increase
in ASARM peptides occurs in HYP teeth. Bone resorption
and osteoclastogenesis is also greatly altered in HYP mice
and in normal mice fed with low-phosphate diets (37–39). In
the HYP mouse, MEPE but not FGF23 reduces osteoclast
number chiefly by impacting on RANKL (receptor activator
for nuclear factor-B ligand) expression (38). Consistent with
these findings, abnormalities in cartilage (chondroclasts) and
bone (osteoclasts), matrix protein expression, and matrix
metalloproteinase-9 localization occur in HYP mice (39, 40).
Thus, these extensive studies support the notion that defec-
tive mineralization and bone abnormalities are not solely
because of the hypophosphatemia and indicate SIBLING
matrix proteins play important roles in mineralization.
In this study, we determined whether increased ASARM
peptides released from MEPE and related SIBLING proteins
(DMP1) contribute directly to the HYP mineralization defect
and whether these peptides interact with PHEX and alter
expression of key bone-related genes. To do this, we first
designed small synthetic PHEX peptides using known struc-
ture data from related M13 Zn metalloendopeptidases. We
then used surface plasmon resonance (SPR) and nuclear
magnetic resonance (NMR) to characterize fully the binding
sites between these novel peptides. These peptides and an in
vitro bone marrow stromal cell (BMSC) culture model al-
lowed us to study the biological roles of ASARM peptides
and PHEX in HYP. We conclude that ASARM peptides are
chiefly responsible for the in vitro mineralization defect in
HYP and likely regulate mineralization and osteoblast-oste-
oclast differentiation.
Materials and Methods
Design of a small synthetic PHEX peptide (SPR4, 4.2 kDa)
that binds to ASARM-PO4
After the cloning of the PHEX gene with the HYP Consortium (1), we
characterized PHEX mutations from several HYP families (41). From
these studies and work with M13 Zn metalloendopeptidases (neprilysin,
endothelin-converting enzymes, and KELL) a substrate-binding site was
deduced (3, 41). Using this information with structural and bioinfor-
matic modeling, several synthetic PHEX peptides were designed. Key
considerations were the PHEX substrate-binding region with Zn-bind-
ing motif (HEFTH). Also important were residues for catalysis, speci-
ficity, Zn sequestration, stabilization of the transition state, and identity
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for the MA clan of M13 Zn metalloendopeptidases. Biomolecular soft-
ware PHYRE and 3D-PSSM (http://www.sbg.bio.ic.ac.uk/phyre/)
were used to model probable structure and optimal folding. Based on
SPR, 1H/15N two-dimensional NMR and biological data (see below), a
single PHEX peptide (4.2 kDa) called SPR4 was found to bind to
ASARM-PO4 peptide (Table 1). PHEX has more than 99% sequence
conservation across species and the Zn-binding motif region used to
design the SPR4 peptide is identical across species. The human ASARM
motif region (DSSESSDSGSSSESDGD) was incorporated into the
ASARM peptides used in these studies. It must be noted that the rat and
mouse ASARM motifs differ by two substitutions, and the rodent/
human consensus sequence is DSSESSXSGSSSESXGD. In the rat both Xs
are replaced by S, and in the mouse, an S and H, respectively. The
physiochemical blueprint and secondary structures would not (predict-
ably) be substantially altered between human and rodent ASARM mo-
tifs by these minor substitutions. In addition, the casein kinase II phos-
phorylation consensus sites remain. Also, the anti-ASARM antibodies
used in this study cross-react with mouse and human MEPE ASARM
epitopes providing further support for the interspecies applicability of
our biological findings. The full-length ASARM peptide(s) used with the
cathepsin cleavage site region (RDDSSESSDSGSSSESDGD) are shown in
Table 1. The SPR4 peptide also has biological activity and is discussed
in more detail in the following sections.
SPR experiments
SPR was used to study the binding between soluble PHEX (sPHEX)
and a biotinylated ASARM-PO4 peptide as well as to a number of
biotinylated control peptides (ASARM and RGD-MEPE) (Table 1). Pure
sPHEX protein was prepared as described previously (5, 42, 43). Neu-
travidin (Pierce, Rockford, IL) was immobilized on the surface of a CM5
sensor chip [4000–5000 response units (RU)] using standard amine cou-
pling chemistry (5). The indicated biotinylated peptides were captured
on individual flow cells, and the remaining unmodified neutravidin
surface was used as the reference surface. Binding of the sPHEX con-
centration series (7.5, 15, 31.5, 62.5, 125, 250, and 500 nm) was studied
at 25 C in 10 mm HEPES (pH 7.4), 150 mm NaCl, 2 mm ZnCl2, 0.005%
surfactant P20 at a flow rate of 5 l/min in a Biacore 3000 instrument
(Biacore Inc., Piscataway, NJ). The experiment was done on two different
CM5 chips with the following surface densities: bio-ASARM-PO4 (629
and 447 RU), bio-ASARM (447 and 407 RU), and bio-RGD-MEPE
(831and 588 RU). The data were analyzed using BiaEvaluation 3.1 soft-
ware (Biacore).
SPR was also used to study the inhibition of the sPHEX and ASARM-
PO4 peptide interaction. For these experiments, a CM5 chip with neu-
travidin-captured biotinylated peptides (bio-ASARM-PO4 447 RU, bio-
ASARM 407 RU, bio-RGD-MEPE 588 RU) was used (Table 1). The
procedure indicated above was modified as follows: Immediately before
analyte injection, a stock solution of experimental SPR4 peptide (or
controls SPR3, SPR5; Table 1) dissolved in binding buffer [10 mm HEPES
(pH 7.4), 150 mm NaCl, 2 mm ZnCl2, 0.005% surfactant P20] was added
to a constant 50 nm PHEX analyte solution to give final peptide con-
centrations of either 0, 0.75, 1.5, 3, 6, 12.5, 25. 50, or 100 m. In this way,
a concentration-dependent inhibition curve was calculated for each of
the peptides as described previously (5), although the SPR4 peptide was
the only one to significantly inhibit the binding. Each Biacore Surface
Plasmon Resonance (SPR) experiment was independently performed
three times for all data points (n  3).
Two-dimensional 1H/15N NMR
Demonstration of SPR4 binding to peptides was obtained after two-
dimensional 1H/15N NMR. SPR4 peptide (1 mg) was first dissolved in
100 l 25 mm acetic acid (pH 3.5) followed by 400 l 50 mm Tris (pH 7)
and 25 m ZnCl2. Peptides dissolved in the same buffer were then added
at different multiples of molar concentrations relative to SPR4 (1–10).
Solutions were then made 6 mm relative to CaCl2 and incubated at 25
C for 1 h before NMR analysis. Samples were then transferred to 5 mm
standard D2O-matched NMR tubes (Shigemi, Tokyo, Japan) for insertion
in to the spectrometer. The 15N heteronuclear single quantum coherence
experiments were carried out on an 800-MHz Bruker Avance NMR
spectrometer with a cryogenically cooled triple-axis probe capable of
delivering gradient pulses, using a pulse sequence containing WATER-
GATE for solvent suppression. All experiments were performed at 25 C.
Each data set was collected using eight scans with 1024 points in 1H and
128 points in 15N. Samples contained 5% D2O, and referencing was
performed relative to 2,2-dimethyl-2-silapentane-5-sulfonic acid, ac-
cording to the procedure established by Wishart et al. (44). The data were
then processed in nmrPipe using linear prediction with twice the num-
ber of collected data points and zero filling to 1600 points. All new peaks
resulting from peptide interactions had a signal to noise ratio of at least
5:1, clearly distinguishing them from the noise using Sparky (45, 46).
Animals
Five male wild-type (WT) and five male HYP mice were used; the
animals in both groups were 6 wk old (The Jackson Laboratory, Bar
Harbor, ME). Hind limbs were collected for primary cell culture, and
calvariae were collected in proteases inhibitor cocktail for protein ex-
traction and further SDS-PAGE analysis (see below).
Cell culture
Culture conditions. Adherent BMSCs were cultured to assess the in vitro
relative osteoblastic/osteoclastic potential of small peptides (ASARM
and SPR4) based on a classical approach. The epiphyses of the bones (i.e.
tibias and femurs) were removed, and whole marrow was flushed from
the diaphyses by centrifugation at 11,500 rpm for 30 sec in standard
-MEM culture medium (Mediatech Inc., Manassas, VA) supplemented
with 10% fetal bovine serum (Mediatech), 10 U/ml penicillin, and 100
g/ml streptomycin. The supernatant was removed, and the cell pellet
was resuspended in fresh standard medium. The cells were plated in
standard 25-cm2 flasks and allowed to grow until confluence. They were
passaged with 0.25% trypsin solution containing 0.02% EDTA (Sigma-
Aldrich, St. Louis, MO). Cells were plated on 24-well plates for miner-
alization assays and on 96-well plastic culture plates for osteoclastic
assessment at a concentration of 10  104 cells per well. Starting 72 h after
seeding (referred to as d 0), nonadherent cells were discarded, and the




SPR3 PHEX-Zn region NH2-GTEYPRSLSYGAIGVIVGHEFTHGFDNNGRKYDKNGNLD-OH
SPR4 PHEX-Zn-designed-peptide NH2-TVNAFYSASTNYPRSLSYGAIGVIVGHEFTHGFDNNGRGENIADNG-OH
SPR5 Control randomer for SPR4 NH2-LKGDHSGGNGNYTGLDYNIPGYFRSTIPFHGEVDKENVAR-OH
SPR6 PHEX-ZN region peptide NH2-AIGVIVGHEFTHGFDNNGRK-OH





SPR4 peptide was also labeled with 15N isotope for all NMR experiments. Specifically, all SPR4 alanine (A) and glycine (G) residues were
labeled except for the last C-terminal glycine. Ahx indicates an N-terminal 6-aminohexanoic acid linker for biotinylated peptides. Nonbioti-
nylated peptides were used for biological experiments, and biotinylated peptides were used as ligands for SPR.
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medium was changed to one that supports osteoblast differentiation
[standard medium plus 10 mm -glycerophosphate (Sigma-Aldrich) and
50 mg/liter ascorbic acid (Sigma-Aldrich)] or osteoclastic development
[50 ng/ml RANKL (Sigma-Aldrich, MO) and 50 ng/ml macrophage
colony-stimulating factor (Sigma-Aldrich)]. These media were used
throughout the rest of the culture period. To evaluate the involvement
of SPR4 and ASARM-PO4 in the regulation of osteoblasts and osteoclasts
growth/differentiation and activity, cells were treated during the cul-
ture period with either 5 m ASARM-PO4 or 10 m SPR4 or both.
Untreated cells were used as controls. The compounds were added to
the culture medium on d 0 and renewed every other day.
Mineralization assay. Monolayers were washed with PBS and fixed in 10%
(vol/vol) formaldehyde (Fisher Scientific, Pittsburgh, PA) at room tem-
perature for 15 min. The monolayers were then washed twice with
excess dH2O before addition of 1 ml of 10 mg/ml alizarin red S (ARS)
solution in 0.2% ammonium (pH 6.36) per well. The plates were incu-
bated at room temperature for 45 min with gentle shaking. After aspi-
ration of the unincorporated dye, the wells were washed six times with
2 ml dH2O while shaking for 5 min. The plates were reaspirated and then
stored at 20 C before dye extraction. For quantification of staining, 500
l 10% (vol/vol) acetic acid was added to each well, and the plate was
incubated at room temperature for 30 min while shaking. The monolayer
was then scraped from the plate with a cell scraper and transferred with
10% (vol/vol) acetic acid to a 1.5-ml microcentrifuge tube. After vor-
texing for 30 sec, the slurry was heated to exactly 85 C for 10 min and
transferred to ice for 5 min. The slurry was then centrifuged at 10,000 
g for 15 min, and 400 l of the supernatant was removed to a new 1.5-ml
microcentrifuge tube, and 150 l 10% ammonium hydroxide was added
to neutralize the pH down to 4.1–4.5. The 150-l aliquots of the super-
natant were read in triplicate at 450 nm in 96-well format using opaque-
walled, transparent-bottomed plates.
Osteoblast alkaline phosphatase (ALP) staining. After 2% formaldehyde
fixation and rinsing, the activity of the plasma membrane-associated
ALP was detected using an ALP leukocyte staining kit (Sigma-Aldrich)
according to the manufacturer’s protocol. The cultures were then rinsed
three times for 5 min each in deionized water, and nuclei were stained
with 4,6-diamidino-2-phenylindole. The percentage of ALP-positive
cells were determined by counting cells in 10 contiguous fields per well
after random starts.
Osteoclasts tartrate-resistant acid phosphatase (TRAcP) staining. Monolayers
were washed once with 100 l PBS and fixed in 50 l formalin for 5 min
at room temperature. Each well was then washed three times with 250
l dH2O before staining. Cells were incubated at 37 C for 60 min with
50 l of a 150 g/ml sodium tartrate solution containing 1 mg/ml
naphthol-1-phosphate and 2.5 mg/ml Fast Violet (Sigma-Aldrich). After
staining, cells were washed twice with dH2O water, and then enzymatic
reaction was blocked with 50 l 4.2 g/ml sodium fluoride aqueous
solution. The monolayers were then washed twice with excess dH2O and
then air dried. The percentage of multinucleated TRAcP-positive oste-
oclasts was determined by counting cells in 10 contiguous fields per well
after random starts.
RT-PCR
RNA extraction and RT. RNA extraction was performed on three wells per
experimental condition. Total RNAs were extracted using the RNeasy
Mini Kit (QIAGEN, Valencia, CA) on each well according to the man-
ufacturer instructions. The purity of total RNA prepared was monitored
by the ratio of absorbance at 260 and 280 nm. Total RNAs were reverse
transcribed into single-stranded cDNA using iScript cDNA synthesis kit
(Bio-Rad Laboratories, CA) from 1 g of total RNA.
Plasmids. Escherichia coli bacteria expressing mouse 3594705 (Transferrin)
plasmids (American Type Culture Collection, Manassas, VA), were cul-
tured on LB medium supplemented with 50 g/ml ampicillin, extracted,
and purified using the QIAfilter Maxi kit (QIAGEN) and then resus-
pended in sterile endotoxin-free saline solution. Plasmid DNA concen-
tration was measured at 260/280 nm. Plasmids were digested by the
specific restriction endonucleases (Invitrogen, Carlsbad, CA), and the
quality of DNA was assessed by 1% agarose gel electrophoresis. Plas-
mids were stocked at 80 C before use.
Real-time PCR. The single-strand cDNA was diluted 1:10, and 20 l was
amplified in 50 l PCR mixture containing 25 l FastStart SYBR Green
Master (FastStart SYBR Green Master PCR Kit; Roche, Mannheim, Ger-
many) and 2.5 l forward and 2.5 l reverse oligo-primers (10 m each).
Amplifications were performed in the Bio-Rad iQ5 Real-Time PCR De-
tection System (Bio-Rad Laboratories, Hercules, CA). The primer se-
quences and product sizes of each amplified marker are shown in Table
2. Quantified data were analyzed with the iCycler analysis software.
Serial dilution of total cDNA was performed from and used as stan-
dards. Results were processed following the manufacturer’s instruc-
tions: 1) checking the PCR products specificity by using the melting
temperature of each product followed by the product sequencing and
2) calculating the variation in PCR product concentration between ex-
perimental groups, normalized by transferrin (housekeeping gene) and
expressed as a percentage of control condition mean values. The accu-
racy of cDNA amplification was assessed by amplifying in the same PCR
the experimental sample cDNA and the same samples supplemented
with a known plasmid concentration for transferrin housekeeping gene,
plotted against a serial dilution plasmid standard curve.
Immunohistochemistry. For immunohistochemistry, cells were cultured
on eight-well tissue culture-treated glass slides for 14 d (BD Biosciences,
Billerica, MA). Before immunohistochemical screening, BMSCs were
extensively washed with PBS to minimize contamination with endog-
enous peptides derived from cell culture media. After culture, cell slides
were incubated with 0.03% H2O2 for 15 min to block endogenous per-
oxidase activity and then blocked with avidin/biotin blocking solution
(Vector Laboratories Inc., Burlingame, CA) for 30 min and finally a 5%
chicken/goat/horse serum solution for 45 min at room temperature.
Samples were immunostained with either lab-designed rabbit poly-
clonal antibodies raised against MEPE ASARM peptide (C-terminal
region) or MEPE mid-region RGD peptide (8, 9, 14) or DMP1 (LF-148)
as described previously (6, 47, 48). Rabbit antibodies raised against the
following peptide were used for screening PHEX: NH2-CMINQYSNYY-
WKKAGL-CONH2. Goat polyclonal anti-FGF23 (sc-16849) was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). All samples
were incubated with antisera for 1 h at room temperature. Negative
control samples were incubated with rabbit IgG (5 g/ml). Samples
stained for MEPE and DMP1 were then incubated with antirabbit bio-
tinylated secondary antibody (1/200) (Vector) for 30 min at room tem-
perature and developed using the Vectastain ABC kit and stable dia-
minobenzidine (Vector). PHEX and FGF-23 staining were developed





Transferrin accatgttgtggtctcacga acagaaggtccttggtggtg 134
PHEX gtggtggtctgtggaatcag agccggctttcttccaata 91
MEPE cccaagagcagcaaaggtag ccgctgtgacatccctttat 215
DMP1 agtgaggaggacagcctgaa gaggctctcgttggactcac 86
RUNX2 ccgtggccttcaaggttgt ttcataacagcggaggcattt 117
Osterix tgaggaagaagcccattcac acttcttctcccgggtgtg 197
MSX2 accacgtcccagcttctagc gctctgcgatggagaggtactg 66
Osteocalcin agcaggagggcaataaggta caagcagggttaagctcaca 111
Osteoprotegerin gttcctgcacagcttcacaa aaacagcccagtgaccattc 120
RANKL agccgagactacggcaagta gcgctcgaaagtacaggaac 207
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using Alexa Fluor 594 donkey antirabbit and Alexa Fluor 488 donkey
antigoat fluorescent antibodies (Invitrogen). All samples were counter-
stained with DAPI, dehydrated and mounted with entellan (EMD
Chemicals, NJ).
Total protein extraction and assay. Total proteins from calvariae were
extracted in 1 ml lysis buffer of T-PER tissue protein extraction reagent
(Pierce). After centrifugation (10 min at 5000 rpm and 4 C), supernatants
were stored at 80 C. Protein concentration was measured using the
bicinchoninic acid protein assay kit (Pierce).
Western blotting
Protein lysates (2.5 mg/sample) were reduced and extracted in lith-
ium dodecyl sulfate sample buffer (Invitrogen) heated for 10 min at 70
C, electrophoresed on NuPAGE Novex 4–12% bis-tris gels (Invitrogen),
and then analyzed by Western blotting using the ECL Advance WB
Detection Kit (GE Healthcare, Piscataway, NJ). Briefly, after SDS-PAGE,
proteins were transferred to nitrocellulose membrane (Bio-Rad). After
transfer, membranes were blocked overnight at 4 C using 5% nonfat
dried milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T; pH
7.4) and incubated for 1 h at 22 C on a rocking platform with the rabbit
polyclonal anti-ASARM (8, 9, 14) (1:2000), rabbit polyclonal anti-DMP1
(LF-148, 1:2000) (6, 47, 48), and goat polyclonal anti-GAPDH (sc-31914,
1:1000; Santa Cruz Biotechnology) antibodies. Membranes were washed
three times in TBS-T and then incubated with secondary antibodies
(peroxidase-conjugated goat antirabbit or peroxidase-conjugated rabbit
antigoat, 1:20,000) for 1 h at room temperature. After washing three
times with TBS-T, the immunoreactive bands were visualized using
enhanced chemiluminescence detection reagents (GE Healthcare, UK)
on a Fluor-S Multi Imager (Bio-Rad). Immunoblot were stripped by
using mild antibody stripping solution (Pierce) and reprobed with an-
other antibody. Band intensities were determined by densitometry using
Quantity One software (Bio-Rad).
Statistical analysis
Statistical analysis was performed using commercially available sta-
tistical software STATISTICA (StatSoft Inc., Tulsa, OK). Differences be-
tween groups were initially analyzed by one-way ANOVA. When F
values for a given variable were found to be significant, the sequentially
rejecting Bonferroni-Holm test was subsequently performed using the
Holm’s adjusted P values. Results were considered to be significantly
different at P  0.05.
Results
ASARM peptide binds directly to sPHEX as revealed by
SPR
Our previous SPR studies indicate that MEPE binds to
sPHEX in vitro (5). These studies also showed that ASARM-
PO4 (a potent inhibitor of mineralization in vivo and in vitro)
competitively inhibits the MEPE-sPHEX protein-protein in-
teraction (3, 5, 9). Here, we extend these studies by demon-
strating that there is a direct interaction between ASARM-
PO4 peptide and sPHEX. To accomplish this, a short
biotinylated ASARM-PO4 peptide (ligand) was captured
onto a neutravidin-coated SPR chip surface. Varying con-
centrations of sPHEX (analyte) were flowed over the surface,
and the binding was measured in real time. A saturable,
concentration-dependent interaction was observed as the
sPHEX analyte concentration was raised from 7.5 to 500 nm
(Fig. 1A), which can be described by a KDapp of 176 nm 40
and a Bmax of 6338  616 (sd) RU (n  3) (Fig. 1B). The
interaction was specific because no binding was observed
when either a biotinylated nonphosphorylated ASARM pep-
tide or a biotinylated RGD-MEPE peptide was immobilized
as control ligand or when proteins other than sPHEX (BSA
and IgG) were used as control analytes. The interaction re-
quires Zn, because no interaction could be measured when
Zn was omitted from the reaction buffer.
FIG. 1. SPR experiments reveal that sPHEX interacts directly with ASARM-PO4 peptide (A and B) and that this interaction is inhibited by
the PHEX SPR4 Peptide (C and D). A, The indicated concentrations of sPHEX were flowed over a captured ASARM-PO4 surface during the
period indicated by the bar, and the SPR response was recorded as a function of time in the displayed sensorgram. Notice that the binding is
concentration dependent and saturable. B, Linear transformation of sensorgram in A with x- and y-coordinates plotted as inverse values for
plasmon RU and sPHEX protein concentration 1/[nM PHEX]. C, The indicated concentrations of SPR4 peptide were flowed over the ASARM-PO4
surface with a constant concentration of sPHEX (50 nM). A concentration-dependent inhibition of the ASARM-PO4-PHEX interaction by SPR4
is observed. Random control SPR5 peptide had no effect. D, Linear transformation of sensorgram C with x- and y-coordinates plotted as inverse
values for plasmon RU and SPR4 peptide concentration 1/[M SPR4]. Each Biacore SPR experiment was independently performed three times
for all data points (n  3). For graph A (PHEX binding to ASARM-PO4), a KDapp of 176  40 nM and a Bmax of 6338  616 (SD) occurs. For
graph B (inhibition of PHEX ASARM-PO4 binding by SPR4), a KIapp of 20  11 M was measured.
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The 4.2-kDa PHEX peptide 4 (SPR4) competitively inhibits
ASARM peptide-sPHEX binding
To further delineate the region on sPHEX that interacts
with the ASARM peptide, a number of peptides were
designed, synthesized, and characterized. We found that
one of these peptides, a 4.2 kDa PHEX synthetic peptide
SPR4, specifically inhibits the binding of sPHEX to the
captured ASARM-PO4 peptide (Fig. 1B). SPR4 inhibits the
interaction in a concentration-dependent, saturable man-
ner with a KIapp of 20  11 m (n  3) (Fig. 1, C and D).
A scrambled control peptide (SPR5) and a shortened form
of the SPR4 peptide (SPR3) had no effect on the sPHEX-
ASARM peptide interaction at concentrations as high as
100 m (data not shown). All peptide sequences are in-
dicated in Table 1.
Two-dimensional 1H/15N NMR demonstrates PHEX-SPR4
peptide (SPR4) binds directly to ASARM peptide
Our SPR experiments showed that the SPR4 peptide com-
petitively inhibits the binding of sPHEX to ASARM-PO4 (Fig.
1). To directly measure the binding of the small synthetic
SPR4 PHEX peptide to ASARM peptide we used two-di-
mensional 1H/15N NMR. Specifically, SPR4 peptide isoto-
pically labeled with 15N on specific amide alanine and gly-
cine residues was incubated with different concentrations of
either ASARM-PO4 or ASARM peptides (see Table 1 for
sequences). Figure 2A shows overlaid 1H/15N spectra of
solutions containing isotopically labeled SPR4 peptide and
nonisotopically labeled ASARM-PO4 peptide (see Materials
and Methods). The overlaid spectra show perturbations only
for SPR4 after peptide binding. The nonisotopic ASARM
peptide ligand remains invisible. The overlaid spectrum in
black represents SPR4 without ASARM-PO4. In contrast, red,
blue, and purple spectra highlight SPR4 peptide in the pres-
ence of 1, 3, and 6 molar equivalents of ASARM-PO4, re-
spectively. These spectra clearly show major perturbations
demonstrating binding between SPR4 and ASARM-PO4.
Figure 2A shows the migration of several resonances from
SPR4 that are affected by increasing the amount of ASARM
present (denoted as -, -, and -shifts). In addition, several
unique peaks (-shifts) are observed as a result of the binding
interaction. Specifically, peaks shift from black (SPR4 only)
to red, blue, and finally purple as ASARM-PO4 concentration
increases and SPR4 isotopic peptide remains constant. Thus,
these data demonstrate SPR4 binds to MEPE ASARM pep-
tide. Control peptides had no effect on the SPR4 NMR spec-
trum (data not shown). Also, overlapping spectra comparing
SPR4 in the presence of nonphosphorylated and phosphor-
ylated ASARM peptide revealed an important role for phos-
phoserines in the binding (Fig. 2B). Specifically, NMR dem-
onstrates that peptide-peptide binding between SPR4 and
ASARM chiefly determines the bound conformation. The
phosphoserine moieties stabilize the interaction, increasing
the binding strength.
FIG. 2. Two-dimensional 1H/15N NMR shows PHEX-SPR4 peptide (SPR4) binds directly to ASARM peptide. A, Overlaid NMR spectra of 15N
isotopically labeled SPR4 peptide with no ASARM peptide (black), 1 molar equivalent ASARM-PO4 peptide (red), 3 molar equivalents
ASARM-PO4 peptide (blue), and 6 molar equivalents (purple). The ASARM-PO4 peptide is nonisotopically labeled; thus, only the SPR4 peptide
1H/15N shifts are visible in the overlaid spectra. The major shifts are boxed and labeled as , , , and  groups, respectively. A dose-dependent
increase in shift occurs as illustrated by the black, red, blue, and purple peaks within each highlighted box. This demonstrates specific binding
of SPR4 peptide to ASARM-PO4 peptide. B, The SPR4 PHEX peptide also binds nonphosphorylated ASARM peptide. An NMR spectrum of SPR4
in the presence of nonphosphorylated and phosphorylated ASARM peptide is shown in B. The overlaid spectra consist of SPR4 peptide without
ASARM peptide (black spectrum), 1 molar equivalent of nonphosphorylated ASARM peptide (blue spectrum), and 1 molar equivalent of
ASARM-PO4 peptide (red). The dashed red box highlights the region where many peaks appear as a result of the interaction between SPR4
and the peptide portion of ASARM. Solid red boxes enclose peaks unique to the phosphorylated peptide and reflect changes in SPR4 that are
specific to interactions with the phosphate moiety at an equivalent 1:1 ratio. Increasing the concentration of ASARM peptide mimics the changes
in the ppm positions observed with ASARM-PO4, but the same degree of change requires more ASARM to achieve compared with ASARM-PO4.
The peaks in the blue boxes are considered unique because they were not observed at the highest concentration analyzed. The results indicate
that peptide-peptide interactions between SPR4 and ASARM largely determine the bound conformation, whereas the phosphate moieties
stabilize the interaction, increasing the binding strength.
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SPR4 (PHEX-related peptide) prevents ASARM-PO4
mediated inhibition of mineralization
As previously reported, ASARM-PO4 peptide inhibits
in vitro mineralization (3, 5, 8 –10, 14). Indeed, WT BMSCs
cells incubated with this peptide display a mineralization
defect similar to HYP BMSCs cultured in the absence of
ASARM peptide. Consistent with the extensive binding
experiments (NMR and SPR), SPR4 peptide was able to
prevent ASARM peptide-mediated inhibition of mineral-
ization in BMSC cultures. Furthermore, SPR4 significantly
restores mineralization in HYP (2.5-fold, P  0.05) com-
pared with control and suppresses ASARM-PO4-induced
mineralization defects in WT cells (Fig. 3, A and B). An
identical dose-dependent reversal also occurs when
sPHEX protein is coincubated with ASARM-PO4, as re-
ported as abstracts (preliminary studies) at recent Inter-
national Bone Mineral Society and American Society for
Bone and Mineral Research meetings (49, 50). Interest-
ingly, in both cell models, ASARM-PO4 significantly alters
the number of ALP-positive cells, suggesting that this
peptide also greatly affects osteoblast development. Con-
sistent with the mineralization findings, coincubation with
SPR4 peptide prevented the ASARM-PO4-induced de-
crease in ALP-positive cells (Fig. 3, C and D).
SPR4 or anti-ASARM antibodies corrects HYP BMSC
mineralization defect
In agreement with previous studies reported by other inves-
tigators (51, 52), HYP and WT cells failed to mineralize when
cocultured (see Fig. 4). This is thought to be secondary to the
action of an unknown diffusible factor (minhibin) secreted by
HYP BMSCs. Control cocultures of WT cells with WT BMSCs
mineralized normally. Also, HYP BMSCs did not mineralize in
the presence of control or rabbit preimmune sera. We extended
these studies to determine whether the unknown minhibin is
ASARM peptide. Consistent with the monoculture experi-
ments, SPR4 rescued the mineralization defect dose depen-
dently in cocultures of WT and HYP BMSC cells. Anti-MEPE
neutralizing antibodies also restored mineralization in both cell
types, with a greater impact when using an antibody targeting
the ASARM motif (Fig. 4). Taken together, the monoculture and
coculture findings provide decisive evidence for the ASARM
peptide(s) as the minhibin in HYP.
ASARM-PO4 suppresses expression of osteoblastic genes
Consistent with the observed decrease in osteoblast num-
ber (Fig. 3C) ASARM-PO4 peptide dramatically altered os-
teoblast-specific gene marker expression. SPR4 peptide also
FIG. 3. Effects of incubation with ASARM-PO4 and/or SPR4 peptides on BMSCs from WT (black bars) or HYP (striped bars) in monoculture.
A, ARS concentration; B, Representative photomicrographs of ARS staining; C, number of ALP-positive cells, represented as a percentage of
total surface and relative to the untreated WT; D, representative photomicrographs of cells stained for ALP. The data represent the mean 
SEM of triplicates from a representative experiment of three separate experiments that were not significantly different (Mann-Whitney U test).
*, P  0.05 vs. matched control cells.
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prevented these changes (Table 3). Specifically, a decrease in
runx2, osterix, and osteocalcin expression occurred with WT
BMSCs supplemented with ASARM-PO4, suggesting that
ASARM-PO4 peptide directly or indirectly suppresses ex-
pression of these osteoblastic markers. Coincubation with
SPR4 and ASARM-PO4 corrected this effect in all cases ex-
cept for msx2. Addition of SPR4 without ASARM-PO4 re-
sulted in a dramatic and significant increase in gene expres-
sion in all cases, presumably by sequestering endogenous
ASARM-PO4. In HYP, addition of ASARM-PO4 had no ef-
fect on expression of the same markers. This is likely due to
endogenous ASARM-PO4 secretion by these cells and thus
saturation. However, as observed with WT cells, addition of
SPR4 peptide dramatically increased expression of all genes
(Table 3). Thus, these in vitro findings are consistent with the
preceding mineralization and binding experiments. Specif-
ically, they support further the conclusion that ASARM-PO4
plays a major role in the bone and mineralization pathology
in HYP.
ASARM-PO4 decreases PHEX and increases FGF23
expression
ASARM-PO4 induced an early decrease in PHEX mRNA
and protein expression at d 3 and protein levels after 14 d
(Fig. 5, A, B, and D). In contrast, PHEX expression was
significantly and markedly increased after SPR4 treatment
(280%, P  0.002). Again, this suggests SPR4 binds
ASARM-PO4 and neutralizes its activity. No other changes
were observed at d 7 or 21 (data not shown). Note, as ex-
pected, no PHEX protein or mRNA was detected in HYP
BMSCs. Consistent with our previous published results,
FGF23 protein levels were increased in HYP (Fig. 5, C and D),
and addition of ASARM-PO4 increased FGF23 protein levels
in HYP and WT BMSCs (10).
SPR4 peptide rescues ASARM peptide-mediated decrease in
DMP1 expression
In WT BMSCs, DMP1 expression paralleled PHEX expres-
sion. Specifically, ASARM-PO4 peptide reduces expression
of DMP1 mRNA and protein, and this was reversed by co-
incubation with SPR4 peptide (Fig. 6, A and B). As with
PHEX, incubation with SPR4 in the absence of ASARM-PO4
results in a dramatic increase in DMP1 expression. With HYP
cells, this pattern is quenched due to either endogenous
FIG. 4. Corrected mineralization after
incubating BMSCs (cocultures; HYP
and WT) with SPR4 peptide and anti-
MEPE antibodies. WT cells were either
cocultured with WT BMSCs (WT-coWT)
or HYP (WT-coHYP), and HYP cells
were cultured with WT cells (HYP-
coWT). A, Representative photomicro-
graphs of ARS staining; B, ARS concen-
tration. The data represent the mean 
SEM of triplicates from a representative
experiment of three separate experi-
ments that were not significantly dif-
ferent (Mann-Whitney U test). *, P 
0.05 vs. matched control.
TABLE 3. Effects of incubation with ASARM-PO4 and/or SPR4




Control 100.0  9.3 100.0  33.4
ASARM-PO4 62.7  9.5a 106.1  19.0
SPR4 526.4  175.7a 340.0  91.8a
ASARM-PO4SPR4 181.5  34.0 21.3  10.3a
Osterix
Control 100.0  24.9 100.0  42.7
ASARM-PO4 52.0  21.0 100.5  10.2
SPR4 372.5  62.7a 630.1  321.8a
ASARM-PO4SPR4 90.2  11.5 189.6  15.5
msx2
Control 100.0  37.4 100.0  21.2
ASARM-PO4 43.5  9.0 77.2  20.3
SPR4 308.5  77.3a 269.6  93.0a
ASARM-PO4SPR4 59.3  18.3 134.0  4.6
Osteocalcin
Control 100.0  48.5 100.0  11.9
ASARM-PO4 53.9  6.4 109.3  13.5
SPR4 1105.9  39.2a 323.6  33.1a
ASARM-PO4SPR4 182.0  77.6 248.3  33.9a
Gene expression was measured by real-time quantitative PCR.
a P  0.05 vs. matched control cells.
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overexpression of ASARM peptides or absence of PHEX
ligand. ASARM-PO4 had no effect on DMP1 mRNA expres-
sion in HYP BMSCs, but SPR4 with or without ASARM-PO4
increased DMP1 immunoreactivity and mRNA expression
(Fig. 6, A and B). Interestingly, although ASARM-PO4 pep-
tide had no effect on DMP1 mRNA expression, a significant
drop in DMP1 immunoreactivity was observed in HYP BM-
SCs, suggesting increased proteolytic degradation. The fact
that coincubation of ASARM-PO4 and SPR4 peptides also
increased DMP1 expression in HYP suggests stoichiometry
and or binding affinities also play a role.
Reduced MEPE protein in HYP and ASARM-treated
BMSCs is also rescued by SPR4
Addition of ASARM-PO4 peptide to WT BMSCs and HYP
BMSCs caused a dramatic drop in MEPE protein immuno-
reactivity as screened using MEPE anti-ASARM antibodies
(Fig. 6D). Also, BMSCs were screened with anti-MEPE an-
tibodies raised against an N-terminal mid-region incorpo-
rating the MEPE RGD motif (anti-MEPE-RGD). With these
antibodies, although WT BMSCs were strongly immunopo-
sitive, HYP BMSCs with and without ASARM peptide were
completely negative and showed no immunoreactivity (data
not shown). Again as with DMP1, this suggests increased
proteolytic degradation of MEPE protein (small ASARM
peptides not detectable). Addition of SPR4 peptide dramat-
ically reversed this and increased MEPE protein immuno-
reactivity in both wild-type and HYP BMSCs (Fig. 6D). With
WT BMSCs, addition of ASARM peptide or SPR4 peptide or
coincubation with SPR4 and ASARM-PO4 had no effect on
MEPE mRNA expression. In dramatic contrast, addition of
ASARM-PO4 peptide to HYP BMSCs resulted in a dramatic
increase in MEPE mRNA expression that was also reversed
by SPR4 peptide (Fig. 6C).
ASARM-PO4 differentially affects OPG/RANKL pathway
in HYP and WT BMSCs
Osteoprotegerin (OPG) gene expression is significantly
increased in WT cells incubated with ASARM-PO4. In
marked contrast, a reverse pattern occurs with HYP cells, and
OPG expression is decreased in the presence of ASARM-PO4
(Fig. 7, A and B). In both cases (HYP and WT), coincubation
with SPR4 and ASARM-PO4 peptides neutralizes this effect.
In the absence of ASARM-PO4, SPR4 peptide significantly
increases OPG expression 5-fold in HYP cells presumably
due to sequestration of endogenous ASARM peptides (Fig.
7B). An inhibition of RANKL expression occurs with HYP
cells supplemented with ASARM-PO4, and a similar trend is
observed in WT cells. However, RANKL expression is mark-
edly increased in the presence of SPR4 peptide for both WT
and HYP cells (Fig. 7, C and D). Again, consistent with
endogenous overexpression of ASARM peptides in HYP
FIG. 5. BMSCs treated with ASARM-PO4 and SPR4 peptides show altered expression of PHEX and FGF-23. Incubation with ASARM-PO4
and/or SPR4 peptides on BMSCs from WT (black bars) or HYP (striped bars) are shown. A, Phex mRNA levels at d 3; B, number of cells
immunostained for PHEX at d 14; C, number of cells immunostained for FGF23 at d 14. The data represent the mean  SEM of triplicates from
a representative experiment of three separate experiments that were not significantly different (Mann-Whitney U test). Results are expressed
as percentage of values for WT untreated cells. *, P  0.05 vs. matched control cells. D, Representative photomicrographs of PHEX and FGF23
immunostaining (20).
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cells, the RANKL/OPG ratio was unchanged in HYP BMSCs
treated with ASARM-PO4 but markedly reduced in WT BM-
SCs. Interestingly, SPR4 peptide in the absence of ASARM-
PO4 peptide dramatically increased the RANKL/OPG ratio
in both WT and HYP cells. This implies the ASARM peptide
alters RANKL/OPG ratio independent of PHEX (Fig. 7, E
and F). Thus, in vitro ASARM-PO4 has no effect on HYP
osteogenic or osteoclastogenic indices presumably due to
endogenous and saturating overexpression of ASARM pep-
tides and absence of PHEX in HYP BMSCs. In contrast, WT
cell markers are dramatically altered by ASARM-PO4. The
reduction in markers of osteoblastogenesis and osteoclasto-
genesis provides mounting evidence for a reduced bone
turnover in the presence of ASARM-PO4. Conversely, SPR4
peptide had the opposite effects to the ASARM peptide on
both WT and HYP cells, presumably by sequestering
ASARM peptides. Thus, SPR4 peptide increases in vitro in-
dices of both osteoblastogenesis and osteoclastogenesis, sug-
gesting a potential for increased bone turnover in vivo.
SPR4 and ASARM-PO4 suppress osteoclastogenesis in WT
BMSCs: evidence for a secondary PHEX ligand
In WT BMSCs, addition of ASARM-PO4 or SPR4 peptide
significantly reduced TRAcP-positive staining. This was re-
versed by coincubation with SPR4 peptide and ASARM-PO4
(Fig. 7G). A marked decrease in cell proliferation was also
noted (data not shown). In contrast, there was no significant
change in the number of TRAcP-positive cells after addition
of ASARM-PO4 to HYP cells. Again, this was likely due to
overexpression of endogenous ASARM peptides by the HYP
cells and signal saturation. Interestingly, SPR4 peptide in the
absence of ASARM-PO4 peptide reduces osteoclast number
in WT but increases it in HYP BMSCs (Fig. 7G). Coincubation
with ASARM-PO4 and SPR4 restores basal levels in WT cells
and produces a slight but significant increase in TRAcP-
positive cells in HYP. Because SPR4 like ASARM-PO4 re-
duces TRAcP activity in only WT BMSCS, SPR4 peptide may
compete with PHEX for a secondary PHEX ligand. In con-
trast, ASARM-PO4 may (by binding to PHEX directly) pre-
vent this secondary PHEX-ligand interaction from occurring.
This is further supported by the finding that coincubation of
WT BMSCs with SPR4 and ASARM-PO4 peptides restores
TRAcP to normal (Fig. 7G).
MEPE and DMP1 proteins are degraded in HYP calvariae
Proteins extracted from HYP and normal mice calvariae
were separated on 4 –12% SDS-PAGE gels and then serially
immunoblotted (Western) with rabbit polyclonal antibod-
ies against MEPE (ASARM region), DMP-1, and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), respec-
tively (Fig. 8). Five calvariae were screened for all groups,
and three representative screens for each group (MEPE,
DMP1, and GAPDH) are shown in Fig. 8A. Figure 8, B and
C, graphically shows chemiluminescent intensity (pixels
FIG. 6. BMSCs treated with ASARM-PO4 and SPR4 peptides show altered expression of DMP1 and MEPE. Incubation with ASARM-PO4 and/or
SPR4 peptides of BMSCs from WT (black bars) or HYP (striped bars). A, DMP1 mRNA levels at d 3; B, DMP1 immunostained surfaces at d
14 (bar graphs and representative photomicrographs); C, MEPE mRNA levels at d 3; D, MEPE-immunostained surfaces at d 14 (bar graphs
and representative photomicrographs). The data represent the mean  SEM of triplicates from a representative experiment of three separate
experiments that were not significantly different (Mann-Whitney U test). Results are expressed as percentage of values for WT untreated cells
*, P  0.05 vs. matched control cells.
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percentage adjusted for volume) for MEPE (B) and DMP1
(C) after normalization for protein and GAPDH control
(Quantity 1 Bio-Rad Software). Although MEPE mRNA
expression is increased in HYP (Fig. 6) (10, 11, 13, 18),
major degradation of MEPE protein (	48%, P  0.0006;
n  5) and DMP1 protein (	68%, P  0.025; n  5) was
detected in HYP mice calvariae (Fig. 8). These findings are
consistent with reports of increased degradation of MEPE
protein in HYP patient teeth despite increased mRNA
expression (21). Thus, increased degradation of these pro-
teins (MEPE and DMP1) is likely responsible for the in-
creased amounts of COOH-terminal, protease-resistant
ASARM peptides in HYP because both proteins contain
ASARM-like motifs (3, 5, 7–9, 14). Also, protease levels in
HYP mice osteoblasts are markedly increased (8, 15, 19,
20). Degradation of matrix proteins is part of the mecha-
nism whereby osteogenesis is inhibited in HYP.
Discussion
Our previous work demonstrated direct binding of PHEX
to MEPE and showed ASARM-PO4 peptide competitively
inhibits this binding (5). More recently, we extended this
study and showed both ASARM peptide and MEPE protein
potently inhibits PHEX enzymic hydrolysis of a nonphysi-
ological fluorogenic peptide substrate (10). Both these stud-
ies provide indirect evidence that the PHEX-MEPE binding
site involves the ASARM motif. For the first time, this study
directly shows that binding between PHEX and MEPE occurs
between the PHEX Zn-binding motif and a short COOH-
terminal region of MEPE consisting of the ASARM motif.
Indeed, not only does PHEX bind specifically to immobilized
ASARM-PO4 peptide but a synthetic PHEX peptide (SPR4)
comprising the Zn binding motif also directly and specifi-
cally binds free ASARM peptide (2.2 kDa). Both phosphor-
FIG. 7. BMSCs incubated with ASARM-PO4 peptide or SPR4 peptide showed altered osteoclastogenesis. Incubation with ASARM-PO4 and/or
SPR4 peptides of BMSCs from WT (black bars) or HYP (striped bars) on osteoclastogenesis are shown. A and B, OPG mRNA levels at d 3 for
WT (A) and HYP (B); C and D, RANKL mRNA levels at d 3 for WT (C) and HYP (D); E and F, RANKL/OPG mRNA ratio at d 3 for WT (E)
and HYP (F); G, TRAcP-immunostained surfaces. The data represent the mean  SEM of triplicates from a representative experiment of three
separate experiments that were not significantly different (Mann-Whitney U test). Results are expressed as percentage of values for WT
untreated cells. *, P  0.05 vs. matched control cells.
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ylated and nonphosphorylated forms of ASARM peptides
bind SPR4 peptide (4.2 kDa) as demonstrated by NMR. The
peptide sequence of both peptides control the bound con-
formation, and the phosphoserine moieties of the ASARM
peptide stabilize the binding by increasing the binding
strength. This may have physiological implications because
a change in casein ectokinase expression and activity, present
on the surface of osteoblasts, occurs in HYP (53, 54).
Mature osteoblasts, osteocytes, odontoblasts, proximal
convoluted tubules of the kidney (luminal side), and saliva
all express MEPE (6, 8, 21, 22, 47–49, 55–57). MEPE is also
present in the circulation at high levels in normal subjects
and age-dependently correlates with serum PO4, PTH, and
bone mineral density (8, 14, 17). In HYP, a marked increase
in MEPE expression (protein and mRNA) and ASARM pep-
tides in serum, bone, and kidney occurs (3, 8, 10–14, 18, 26,
50). SIBLING and MEPE ASARM peptides amass in bone in
regions associated with hyperosteoidosis, and this is likely a
key reason for the mineralization pathophysiology (3, 8).
Indeed, ASARM peptides are potent inhibitors of mineral-
ization, and this is consistent with other similar peptides
such as salivary statherin and osteopontin ASARM peptides
(3, 5, 8, 9, 58–60). For the first time, we show in this study
that ASARM peptide(s) are the primary HYP osteoblast fac-
tors inhibiting mineralization in vitro (minhibin). Anti-
ASARM antibodies and SPR4 peptide that binds to ASARM
peptides demonstrated this. Specifically, a correction of the
mineralization defect occurred after incubation with SPR4 or
anti-ASARM polyclonals in monocultures or cocultures of
HYP and WT BMSCs.
Also in this study, we found that ASARM peptides induce
a marked significant decrease in the expression of the os-
teoblastic markers (runx2, osterix, msx2, and osteocalcin) as
well as in the number of osteoblasts and ALP-positive cells.
Consistent with this, a decrease in osteoblast cell numbers
and a significant decline in the number of ALP-positive cells
also occurred. Coincubation with SPR4 reversed this. In HYP
cells, because of constitutive overexpression of endogenous
ASARM peptide, addition of synthetic ASARM peptide had
no significant effect. However, as with WT BMSCs, SPR4
peptide dramatically increased expression of these markers
by sequestering free ASARM peptides. Thus, ASARM pep-
tides reduce osteoblastogenesis, and SPR4 synthetic PHEX
peptide reverses this and potently up-regulates osteoblastic
markers.
In HYP, a decrease in bone resorption, osteoclast number,
and RANKL expression and a suppression of osteoblastic
markers occurs (38–40, 61). NPT2a/ (Na-dependent phos-
phate cotransporter) mice also display a decrease in oste-
oclast numbers likely mediated in part directly or indirectly
by hypophosphatemia (35, 37). Of note, recombinant MEPE
but not FGF23 inhibits osteoclast-like cell formation from
induced WT BMSCs in culture (38). Bone formation and bone
resorption are regulated through multiple mechanisms. One
of the bone resorption mechanisms involves changes in the
RANKL/OPG system and thus osteoclastogenesis (62, 63). In
this study, suppression of osteoclastogenesis and an in-
creased RANKL/OPG ratio occurred in WT BMSCs treated
with macrophage colony-stimulating factor and supple-
mented with ASARM peptides. SPR4 peptide induced an
opposite effect and increased osteoclastogenesis by increas-
ing RANKL expression. Thus, in vitro ASARM-PO4 and SPR4
peptides have opposite effects on osteoclastogenesis mark-
ers, and SPR4 binds and neutralizes ASARM peptide activity.
Because of endogenous and constitutive overexpression of
ASARM peptides in HYP, synthetic ASARM peptides had
less of an effect but did decrease both RANKL and OPG
mRNA expression. Our results are consistent with reports
that recombinant MEPE inhibits osteoclast-like cell forma-
tion in BMSC cell cultures (38). Thus, like BMSCs from HYP
mice, ASARM-PO4-treated BMSCs have decreased oste-
oclastogenic gene markers.
Because the ASARM peptide clearly binds to PHEX and
has potent in vitro anti-mineralization effects and suppresses
bone formation and resorption markers in vitro, we next
focused on PHEX expression (mRNA and protein). Remark-
ably, WT BMSCs incubated with ASARM-PO4 displayed a
marked decrease in PHEX protein and mRNA with increased
FGF23 protein levels. The increase in FGF23 by ASARM-PO4
is consistent with our previously reported studies (10). Again
co incubation with equimolar SPR4 peptide neutralized this
effect likely because of sequestration and inactivation of
ASARM peptide. A significant and marked increase in PHEX
protein and mRNA occurred in cells cultured with SPR4
without ASARM peptide. Thus, this data supports the notion
that ASARM peptide not only binds to PHEX but also sup-
presses PHEX expression (mRNA and protein) and this in
turn also affects mineralization. The mechanism whereby
ASARM peptide causes this (transcription, mRNA stability,
or targeted proteolysis) is under investigation. Because loss
FIG. 8. MEPE and DMP1 proteins are degraded
in HYP mice calvariae. A, Chemiluminescent
Western blots of HYP and WT calvariae screened
with MEPE, DMP1, and GAPDH antibodies as
indicated; B, adjusted pixel intensity of anti-
MEPE blot; C, adjusted pixel intensity of anti-
DMP1 blot. WT are left and HYP right on re-
spective histograms. Calvariae from five male
WT and HYP mice were used (n  5; HYP and
WT). Three separate representative calvariae
are shown for WT and HYP.
1768 Endocrinology, April 2008, 149(4):1757–1772 Martin et al. • ASARM Peptides, PHEX, and SIBLING Proteins in HYP
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 May 2015. at 07:22 For personal use only. No other uses without permission. . All rights reserved.
of PHEX activity results in increased FGF23, this novel path-
way is physiologically important.
ASARM peptides markedly affect mineralization and
bone marker expression (osteoblastic and osteoclastic) and
contribute to the HYP mineralization defect in vitro. In WT
cultures, ASARM peptides likely inhibit mineralization by
binding hydroxyapatite directly and suppressing osteoblas-
togenesis and osteoclastogenesis markers. However, as men-
tioned, the peptide also suppresses protein and mRNA ex-
pression of PHEX and coordinately increases expression of
FGF23. This is consistent with our published in vitro and ex
vivo findings that show both increased FGF23 expression and
direct inhibition of PHEX enzymic fluorogenic hydrolysis by
MEPE and ASARM peptides (10). Indeed, WT BMSC cul-
tures, containing enhanced green fluorescence protein (GFP)
driven by an FGF23 promoter, showed markedly increased
GFP fluorescence compared with non-ASARM-peptide-
treated cultures (10). Also, fluorescence remained constitu-
tively high in control HYP BMSC cultures containing the
same enhanced GFP FGF23-promoter construct. For the first
time, this study shows a direct inhibition of the ASARM-PO4
peptide-induced increase in FGF23 expression by a small
synthetic PHEX peptide SPR4. More importantly, SPR4 with-
out ASARM-PO4 peptide decreases FGF23 protein expres-
sion in WT and HYP BMSCs. The implications are that SPR4
will have similar in vivo properties. If this is the case, the
peptide may well be of therapeutic use in diseases where
FGF23 expression is increased and mineralization is
defective.
Another important feature of the ARHR and likely HYP
phenotype is DMP1, an important matrix protein needed for
normal mineralization and phosphate homeostasis. Indeed,
DMP1-null mutants are phenotypically similar to HYP mice,
and mutations in DMP1 are responsible for ARHR (34, 64).
Also, increased HYP osteoblast protease levels leads to ex-
cessive degradation of the extracellular matrix and increased
protease-resistant ASARM peptides (3, 8, 15, 19, 20). We have
shown that treatment of HYP mice with protease inhibitors
partially corrects the mineralization defect with a commen-
surate decrease in ASARM peptides (8). Also marked deg-
radation of MEPE protein occurs in HYP teeth (21). Consis-
tent with this, our study demonstrates degradation of both
DMP1 and MEPE protein in HYP calvarial cultures. Of fur-
ther note, our data also show that in vitro addition of ASARM
peptide increases degradation of MEPE and DMP1 protein in
BMSC cultures (reversed by coincubation with SPR4 pep-
tide). As mentioned, increased osteoblastic protease activity
and expression is a key feature of the HYP phenotype (8, 15,
19, 20). Because PHEX is defective in HYP and PHEX protein
is suppressed by ASARM peptides in vitro, loss of PHEX is
likely the primary link to increased protease activity and
expression. Thus, we conclude loss of PHEX function leads
to excess osteoblastic protease expression, increased MEPE
expression, excessive degradation of both MEPE and DMP1,
and release of protease-resistant ASARM peptides from both
DMP1 and MEPE.
Figure 9 shows the remarkable biological conservation of
the ASARM motif from DMP1 and MEPE across species and
over millions of years of evolution. Species as diverse as the
armadillo and duck-billed platypus still retain this feature.
The motif also occurs in MEPE protein at the tip and terminal
end of the protein COOH terminus. In DMP-1, the ASARM
motif also occurs at the COOH terminus but unlike MEPE is
repeated and more importantly capped by an additional
27–28 terminal residues. This DMP1 COOH region is labeled
as the minfostin motif in Fig. 9. A frameshift mutation that
extends this minfostin motif results in ARHR. Clearly, pro-
teolytic degradation of both DMP1, a mineralization pro-
moter (minfostin), and MEPE will generate excess amounts
of protease-resistant ASARM peptides (minhibins) exacer-
bated by overexpression of MEPE in HYP. Of note, both
DMP1 and MEPE retain consensus cleavage sites for cathep-
sin K and B in positions that would precisely release the
ASARM peptides. Thus, the cathepsin cleavage sites in
MEPE and DMP1 may be of physiological relevance because
these sites are not conserved elsewhere and occur infre-
quently within these proteins.
The experiments described in this paper and previous
work by us and others allows us to propose a model for the
role of MEPE, DMP1, ASARM peptides, PHEX, and FGF23
in bone renal phosphate metabolism. PHEX plays a central
role by specifically binding accessible ASARM motifs or free
ASARM peptides. There is evidence that PHEX may also
hydrolyze and inactivate free ASARM peptides (43). These
peptides are otherwise exquisitely resistant to proteolysis (3).
The evidence for MEPE and ASARM peptides specifically
binding to PHEX (a Zn-metalloendopeptidase) is unequiv-
ocal. In view of the similarities between DMP1 and MEPE
ASARM peptides, binding experiments investigating inter-
actions between DMP1 and PHEX may also prove informa-
tive. Intriguingly, matrix metalloproteinase-9, a known Zn-
metalloendopeptidase DMP1-binding partner, is markedly
reduced in HYP hypertrophic chondrocytes (39). Of note,
there are two striking features in DMP1 that contrast with
MEPE. The first is the presence of a 27-residue minfostin
motif that terminates and caps the ASARM motif region of
DMP1 (see Fig. 9). The second is the presence of multiple
repeats of the ASARM motif N terminal and contiguous to
the DMP1 minfostin motif. As mentioned previously, a
frameshift mutation in the DMP1 minfostin motif that ex-
tends the sequence length by a few residues and alters the
amino acid sequence causes ARHR (see Fig. 9) (34, 64). Also,
the mutated DMP1 protein, like the wild-type DMP1, is se-
creted. Thus, the DMP1 minfostin motif may play a signaling
or epistatic role in coordinating mineralization. MEPE or
ASARM peptides may regulate this process by competing for
PHEX binding with other ligands or substrates. This model
is also consistent with the finding that double MEPE/PHEX-
null mutants retain a mineralization and phosphate defect
(23).
In conclusion, this study demonstrates that PHEX binds to
MEPE via the PHEX Zn-binding motif and the MEPE
ASARM motif. ASARM peptides are responsible for the min-
eralization defect in HYP BMSCs in vitro and mimic the HYP
phenotype. The ASARM peptide inhibition of mineralization
is likely because of a combination of direct binding to hy-
droxyapatite crystals and decreased expression of PHEX.
Although speculative, ASARM peptide or MEPE protein
may also act by competitive prevention of PHEX binding to
undefined ligands or substrates. The reduced PHEX expres-
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sion induced by ASARM peptides is likely responsible for the
increase in FGF23 expression. ASARM peptides also de-
crease both osteoblastic gene expression and osteoclast dif-
ferentiation by decreasing the RANKL/OPG ratio. A small
4.2-kDa synthetic PHEX-related peptide (SPR4), incorporat-
ing the Zn-binding region, reverses the ASARM-mediated
changes and dramatically reduces FGF23 protein expression
in WT and HYP BMSCs. The SPR4 peptide may well be
pharmaceutically useful to treat mineralization and hy-
pophosphatemia disorders involving FGF23 and ASARM
peptides. Also, based on these findings, it is likely that direct
or indirect interactions between DMP1, MEPE, and PHEX are
important for mineralization and phosphate homeostasis.
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